Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Intimate Rose vs NuuVim

Intimate Rose
Graded #137

Lower grade

vs+2
NuuVim
Graded #101

Higher grade

The verdict

NuuVim takes it — 71.1/100 to 69.1/100, but only just.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound. Intimate Rose is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +32
65
97
Dose & formulationEven
96
96
Clinical oversightIntimate Rose +34
76
42
Labs & monitoringIntimate Rose +2
52
50
FulfillmentIntimate Rose +3
64
61
Contract termsNuuVim +18
37
55
Intimate Rose · left barNuuVim · right bar

The numbers

MetricIntimate RoseNuuVim
WeighScore69.1/10071.1/100
GradeCC
Scorecard rank#137#101
Semaglutide$169/mo (all doses, compounded)$79/mo (all doses, compounded)
Tirzepatide$169/mo (all doses, compounded)$133/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Intimate Rose

Graded #137 · C

Strengths

  • Transparent pricing from 169 dollars per month shown upfront, not gated behind intake
  • Medication and free delivery included, HSA and FSA eligible, no contract
  • Backed by an established women's-health brand using the OpenLoop provider network

Where it loses points

  • State availability not published
  • Oral compounded GLP-1 only; no injectable option shown
  • No specific compounding pharmacy named (network fulfillment via OpenLoop)
NuuVim

Graded #101 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard